However, plasma plasminogen activator inhibitor-1 (PAI-1), a marker associated with increased thrombosis risk, increased by 40.9% in the morning group but remained unchanged in the evening group, suggesting evening administration might be safer (73). The gene discussed is SERPINE1; the disease is Venous thrombosis.